Eva Hellström‐lindberg

Eva Hellström‐lindberg's AcademicInfluence.com Rankings

Philosophy

#9902

World Rank

#13526

Historical Rank

Logic

#6854

World Rank

#8409

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Eva Hellström‐lindberg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Eva Hellström‐lindberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. (2009) (4395)
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. (2010) (878)
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. (2013) (535)
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. (2011) (466)
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. (2011) (442)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life (2003) (428)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. (2011) (413)
Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studies (1995) (357)
Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. (1998) (301)
Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model (1997) (296)
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. (2014) (277)
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts (2008) (276)
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. (2008) (269)
Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. (2000) (257)
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia (2010) (255)
Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells (2018) (251)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. (2022) (249)
Persistent malignant stem cells in del(5q) myelodysplasia in remission. (2010) (245)
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients (2007) (240)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. (2020) (238)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2019) (237)
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells (2010) (216)
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes (2015) (197)
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. (2005) (184)
The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia : Rationale and Important Changes (2009) (177)
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes (2011) (176)
Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. (2002) (171)
Gene expression profiling of CD34+ cells in patients with the 5q− syndrome (2007) (165)
Lung transplantation in telomerase mutation carriers with pulmonary fibrosis (2014) (154)
The WHO classification of MDS does make a difference. (2004) (146)
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. (2018) (146)
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. (2009) (143)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups (2019) (141)
Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia (2010) (127)
The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts (2008) (126)
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine * (2010) (123)
Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. (1997) (123)
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial (2013) (117)
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. (2010) (116)
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) (2014) (116)
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia (2018) (115)
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML (2018) (113)
The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. (2007) (108)
Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes (2008) (105)
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. (2005) (103)
Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells (1999) (103)
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression (2009) (102)
Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. (2007) (100)
Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. (2012) (97)
Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee (2015) (95)
A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. (1993) (91)
The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts (2013) (89)
Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome (2010) (88)
Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival (2006) (87)
Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells. (2004) (87)
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression (2010) (80)
A predictive model for the clinical response to low dose ara‐C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia (1992) (80)
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. (2019) (74)
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial (2010) (72)
Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C (2010) (70)
Myelodysplastic syndromes: biology and treatment (2009) (69)
A patient-oriented approach to treatment of myelodysplastic syndromes. (1998) (67)
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group (2012) (67)
Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. (2008) (62)
Validation of the revised international prognostic scoring system (IPSS‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry (2015) (62)
Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia following Myelodysplastic Syndrome (2007) (57)
Quality of life, physical function and MRI T2* in elderly low‐risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions (2011) (57)
Gene expression and risk of leukemic transformation in myelodysplasia. (2017) (56)
Freezing induces artificial cleavage of apoptosis-related proteins in human bone marrow cells. (2000) (55)
Maintenance treatment with azacytidine for patients with high‐risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy (2010) (54)
The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions (2018) (53)
SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells. (2017) (53)
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study (2018) (52)
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. (2010) (52)
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Commentary (2005) (52)
Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells (2017) (52)
Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission (2008) (51)
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial (2014) (51)
Achievements in Understanding and Treatment of Myelodysplastic Syndromes. (2000) (50)
The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes (2017) (47)
Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. (2008) (45)
Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells. (2009) (45)
Myelodysplastic syndromes: moving towards personalized management (2020) (44)
changes of myeloid neoplasms and acute leukemia: rationale and important The 2008 revision of the World Health Organization (WHO) classification (2013) (43)
Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes. (2013) (43)
Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease (2017) (43)
The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo (2002) (43)
G‐ and GM‐CSF in oncology and oncological haematology (1994) (42)
Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts (2015) (40)
Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts (2001) (40)
Early mitochondrial alterations in ATRA-induced cell death (2006) (39)
The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. (2017) (38)
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. (2006) (37)
The role of JAK2 mutations in RARS and other MDS. (2008) (37)
Antiapoptotic Role of Growth Factors in the Myelodysplastic Syndromes: Concordance Between In vitro and In vivo Observations (2005) (37)
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease (2003) (36)
Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G‐CSF (2009) (36)
Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers. (2009) (36)
Approach to anemia associated with myelodysplastic syndromes. (2003) (36)
A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS (2011) (35)
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations (2016) (35)
Recombinant human granulocyte‐macrophage colony‐stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes (1993) (35)
Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up (2019) (35)
A pilot phase I dose finding safety study of the thrombopoietin‐receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine (2014) (34)
The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro (2001) (34)
The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS) (2008) (34)
Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register (2018) (33)
Mutations in histone modulators are associated with prolonged survival during azacitidine therapy (2015) (33)
Management of anemia associated with myelodysplastic syndrome. (2005) (32)
Cobalt release from glazed earthenware: Observations in a case of lead poisoning. (2007) (32)
Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes. (2013) (32)
Supportive care, growth factors, and new therapies in myelodysplastic syndromes. (2008) (32)
Erythropoietins should be used according to guidelines. (2008) (31)
Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. (2005) (31)
Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. (2006) (30)
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study (2014) (29)
RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004). (2009) (29)
Analysis of CD34‐positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry (1996) (29)
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes (2017) (29)
Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39. (1999) (28)
Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome (2015) (28)
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry (2019) (28)
Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm. (2018) (27)
Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia (2021) (27)
Erythropoiesis stimulating agents and other growth factors in low-risk MDS. (2013) (25)
Treatment of adult myelodysplastic syndromes. (1999) (25)
Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide (2012) (25)
A pharmacodynamic study of 5-azacytidine in the P39 cell line. (2006) (25)
appreci8: a pipeline for precise variant calling integrating 8 tools (2018) (24)
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes (2019) (24)
Quality of Life and Economic Impact of Red Blood Cell (RBC) Transfusions on Patients with Myelodysplastic Syndromes (MDS). (2004) (23)
Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity Are Linked to Clinical Responses to 5-Azacytidine (2020) (23)
Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry (2011) (23)
Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome (2020) (22)
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes (2009) (22)
Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome (2016) (22)
Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality (2016) (22)
Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide (2011) (21)
Treatment with Erythropoietin and G-CSF Improves Survival in MDS Patients with Low Transfusion Need. (2006) (21)
Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q (2013) (20)
Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality. (2010) (19)
Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry (2016) (19)
Lead poisoning from souvenir earthenware (2006) (19)
New clues to the molecular pathogenesis of myelodysplastic syndromes. (2010) (18)
Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome (2022) (18)
Spontaneous and cytokine‐induced thrombocytopenia in myelodysplastic syndromes: serum thrombopoietin levels and bone marrow morphology (1999) (17)
Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes. (2015) (17)
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. (2018) (17)
Stem cell transplantation from identical twins in patients with myelodysplastic syndromes (2005) (17)
Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT (2011) (17)
Peripheral blood neutrophil morphology reflects bone marrow dysplasia in myelodysplastic syndromes (1995) (17)
Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia (2009) (16)
Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors. (2004) (16)
Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia. (2022) (16)
Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy (2008) (16)
A longer duration of red blood cell storage is associated with a lower hemoglobin increase after blood transfusion: a cohort study (2019) (15)
Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation (2014) (15)
Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with myelodysplastic syndrome (MDS): Preliminary results of a phase 1/2 study (2007) (15)
High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia (2015) (14)
High-dose chemotherapy and APSCT as a potential cure for relapsing hemolysing AILD. (2001) (14)
Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry (2012) (12)
Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy. (2007) (12)
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update (2008) (12)
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2020) (12)
Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen. (2009) (12)
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance (2017) (12)
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update (2008) (12)
Low-dose ara-C in myelodysplastic syndromes (MDS) and acute leukemia following MDS: proposal for a predictive model. (1994) (11)
Recent Advances in Myelodysplastic Syndromes (1998) (11)
Significance of JAK2 and TET2 mutations in myelodysplastic syndromes. (2010) (11)
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies (2014) (11)
Time-dependent decision analysis: Stable disease in azacitidine (AZA)-treated patients (pts) with higher-risk MDS. (2010) (11)
Somatic Mutation of SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts (2011) (10)
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome (2020) (10)
Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial (2008) (10)
A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes (2019) (9)
GFI136N as a therapeutic and prognostic marker for myelodysplastic syndrome (2016) (9)
Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients (2014) (9)
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms (2020) (9)
H-Net, the European Network for Harmonization of Training in Hematology, and its policy (2012) (9)
Marked down‐regulation of nucleophosmin‐1 is associated with advanced del(5q) myelodysplastic syndrome (2011) (9)
A European strategy for targeted education in hematology (2013) (9)
Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry (2010) (9)
7 Management of 1000 patients with low- and intermediate-1 risk myelodysplastic syndromes in the European LeukemiaNet MDS Registry (2011) (9)
Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR) (2008) (8)
Erratum: The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes (The Journal of clinical investigation (2017) 127 6 (2206-2221) PII: 96202) (2017) (8)
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q) (2017) (8)
Long-Term Cytogenetic Follow-up of MDS Patients with 5q- Treated within the MDS-003 (CC-5013-MDS-003) Study: Evolution to Complex Clones and Progression to AML. (2008) (8)
Towards a joint definition of European hematology (2012) (8)
Treatment of high-risk MDS patients (pts) with -7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): Effects on overall survival (OS) (2008) (8)
Myelodysplastic syndromes: an historical perspective. (2008) (7)
Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes (2018) (7)
Identification of Gene Expression Based Prognostic Markers in the Hematopoietic Stem Cells of Patients with Myelodysplastic Syndromes (2012) (6)
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective (2020) (6)
O-001 Clinical and biological implications of gene mutations in MDS (2013) (6)
C014 Expression of p53 or cytoplasmic nucleophosmine associated with increased risk of disease progression in myelodysplastic syndrome with isolated del(5q) (2009) (5)
Erythropoiesis-stimulating agents in myelodysplastic syndromes (2010) (5)
Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population‐based study (2020) (5)
Prediction of response to G-CSF and epo treatment for the anaemia of myelodysplastic syndromes (MDS) (1994) (5)
“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)” (2022) (5)
Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs) (2015) (4)
recommendations from the European LeukemiaNet Diagnosis and treatment of primary myelodysplastic syndromes in adults (2013) (4)
Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy From the European Leukemianet Low Risk MDS (EUMDS) Registry (2012) (4)
A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. (2021) (4)
Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities (2009) (4)
In vitro suspension culture reactions to 1,25 dihydroxyvitamin D3 in relation to bone marrow morphology and prognosis in patients with myelodysplastic syndromes. (1992) (4)
Identification of Novel Somatic Mutations in SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts and Other Common Cancers (2011) (4)
Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis (2011) (3)
Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry (2015) (3)
Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004) (2010) (3)
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation (2021) (3)
Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA) (2008) (3)
High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic (2012) (3)
Variable growth in vitro of chromosomally different stem cells in myelodysplastic syndromes. (1993) (3)
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes. (2023) (3)
Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment (2018) (3)
Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs (2022) (3)
Resistance to Lenalidomide in Del(5q) MDS Is Mediated By Inhibition of Drug-Induced Megakaryocytic Differentiation (2018) (3)
34 Health-related quality of life in low-risk MDS patients from the European LeukemiaNet Registry: Correlation with age, gender and decreased survival (2011) (2)
The EHA Research Roadmap: Malignant Myeloid Diseases (2021) (2)
Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA) (2008) (2)
EFFECT OF AZACITIDINE (AZA) vs LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) (2008) (2)
Association Between Gene Expression Profiles and Commonly Mutated Genes In The Hematopoietic Stem Cells Of Patients With Myelodysplastic Syndromes (2013) (2)
Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: Clinical and molecular genetic prognostic factors in a Nordic population. (2021) (2)
P136 Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need (2007) (2)
Factors considered in the 2008 WHO classification of myeloid neoplasms and acute leukemias (2010) (2)
Relationship of progression to acute myeloid leukemia (AML) from myelodysplastic syndrome (MDS) and cytogenetic status (2008) (2)
IDENTIFICATION OF ABERRANTLY SPLICED GENES AND DEREGULATED PATHWAYS/GENE ONTOLOGY THEMES IN MYELODYSPLASTIC SYNDROME PATIENTS WITH SPLICING FACTOR GENE MUTATIONS (2017) (2)
Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome, (2011) (2)
myelodysplastic syndromes - of 5q The molecular signature of MDS stem cells supports a stem-cell origin (2013) (2)
Cause of death and excess mortality in patients with lower‐risk myelodysplastic syndromes (MDS): A report from the European MDS registry (2022) (2)
Clinical manifestations of clonal hematopoiesis: What has SF3B1-mutant MDS taught us? (2022) (2)
Health-Related Quality of Life In Newly Diagnosed Low Risk and Intermediate-1 Risk MDS: Report on the First 683 Patients From the European LeukemiaNet Registry (2010) (2)
58 Interaction of karyotype complexity and response on overall survival and AML progression in lenalidomide-treated Low/INT-1 risk del (5q) MDS patients (2011) (2)
Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry (2013) (2)
Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study (2013) (2)
Multiple hypermethylated genes are potential in vivo targets of demethylating agents (2003) (2)
The European Hematology Curriculum: An Electronic Passport Promoting Professional Competence and Mobility (2018) (2)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (2)
Next-Generation Sequencing Reveals a T Cell Receptor Signature Characteristic of Patients with Aplastic Anemia (2018) (2)
P040 Hypomethylation and apoptosis in 5-azacytidine treated myeloid cells (2007) (2)
Prognostic Value of Early Drop in Platelets in Lower-Risk MDS. A Sub-Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry (2017) (2)
Mutation Analysis of TET2 Reveals the Clonal Nature of Refractory Anemia with Ring Sideroblasts (2010) (2)
Granulocyte-Macrophage Progenitors (GMPs) Express Low Adhesive Potential and High CXCR-4 Levels (2013) (2)
Involvement and intrinsic deficiencies of hematopoietic stem cells in MDS patients with trisomy 8 (2001) (2)
O-17 Thalidomide analogue CC5013 (revlimid) selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5Q deletion (2005) (2)
p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study (2014) (2)
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. (2018) (2)
Patients with Del(5q) MDS Who Fail to Achieve Erythroid or Cytogenetic Remission After Treatment with Lenalidomide Have An Increased Risk for Clonal Evolution and AML Progression. (2009) (2)
Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS. (2008) (2)
Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion. (2006) (1)
P-41 Aberrant mitochondrial iron distribution and maturation arrest characterizes early erythroid precursors in low-risk myelodysplastic syndromes (2005) (1)
Differential Expression of Genes Related to JAK-STAT Pathway Activation or Megakaryocyte Differentiation/Maturation in CD34+ Cells from Patients with Refractory Anemia with Ringed Sideroblasts and Thrombocytosis (RARS-T). (2007) (1)
Long-Term Clonal Inversion in an MDS-RS Case with Dual SF3B1 Mutations (2022) (1)
C023 Expression profiling of CD34+ cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes (2007) (1)
S838 TRANSFUSION DEPENDENCY IS ASSOCIATED WITH PRESENCE OF TOXIC IRON SPECIES AND INFERIOR SURVIVAL IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (2019) (1)
Adult-Onset Ataxia With Neuropathy and White Matter Abnormalities Due to a Novel SAMD9L Variant (2021) (1)
Using a Hematology Curriculum in a Web Portfolio Environment (2011) (1)
NEW INSIGHTS INTO THE BIOLOGY OF REFRACTORY ANEMIA WITH RING SIDEROBLASTS (RARS) AND IDENTIFICATION OF ERYTHROID G-CSF TARGETS BY GENE EXPRESSION PROFILING (2009) (1)
Impact of Red Blood Cell Transfusions on Survival in Lower-Risk MDS Patients Included in the European Leukemianet MDS (EUMDS) Registry (2017) (1)
p 53 protein expression independently predicts outcome in patients with lowerrisk lowerrisk lowerrisk myelodysplastic syndromes with del ( 5 q ) (1)
m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis. (2023) (1)
P-18 A new prognostic score foroutcome of patients with high-risk myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (SAML) after intensive antileukemic treatment (2005) (1)
Gene Expression Profiling of Day 7 Erythroblasts from RARS Before and after Treatment with G-CSF. (2007) (1)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (1)
The Impact of Diabetes Mellitus As Comorbid Condition, in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)— a Study of the European Leukemianet-Based MDS (EUMDS) Registry (2017) (1)
P128 Transfusion independence (TI) in patients with myelodysplastic syndromes (MDS) treated with azacitidine (AZA) (2009) (1)
Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk mds and secondary aml treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups (2001) (1)
37 Low-risk MDS; transfusion therapy, growth factors and the European view on lenalidomide (2009) (1)
Molecular Profiling In A Population Based Cohort Of Nordic Myelodysplastic Syndrome Patients (2016) (1)
Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival (2018) (1)
Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry (2016) (1)
296 Telomere shortening is associated with AML progression in patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide (2011) (1)
Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells (2010) (1)
Multicenter next-generation sequencing studies between theory and practice: harmonization of data analysis using real world myelodysplastic syndrome data. (2020) (1)
Short Telomeres Before Lenalidomide Treatment Predict Leukemic Progression In Patients with Myelodysplastic Syndrome and Deletion 5q (2010) (1)
221 Occurrence of trisomy 8 (+8) in patients with Low- or Int-1-risk MDS with deletion 5q [del(5q)] treated with lenalidomide (2011) (1)
IDENTIFICATION OF ABERRANT SPLICING EVENTS IN MYELODYSPLASTIC SYNDROME PATIENTS WITH SPLICING FACTOR GENE MUTATIONS (2017) (1)
168 Low-dose chemotherapy in MDS (1997) (1)
MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination (2018) (1)
Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia (2022) (1)
European Registry for Low Risk and Intermediate-1 Risk MDS: Base Line Report On First 400 Registered Patients. (2009) (1)
S168: ERYTHROPOIETIN STIMULATION AGENTS SIGNIFICANTLY IMPROVES OUTCOME IN LOWER RISK MDS. (2022) (1)
Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes (2015) (1)
Clonal Heterogeneity in the 5q- Syndrome: NPMc+ and p53 Expressing Progenitors Are Insensitive to Lenalidomide Treatment and Expand at Disease Progression (2008) (1)
Synergistic effect of G-CSF and epo on the anaemia in patients with MDS. Evidence for increased erythropoietic effectiveness rather than expansion (1994) (1)
135 IN VITRO AZACITIDINE CULTURE INDUCES DNA DEMETHYLATION AND INCREASED MRNA-LEVELS IN PRIMARY MDS PROGENITOR CELLS (2015) (1)
A Prognostic Classifier Based on Early Platelet Drop in Lower-Risk MDS. a Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry (2017) (1)
Abstract: treatment of patients with myelodysplastic syndromes with G-CSF and erythropoietin (1993) (0)
CLINICAL AND MOLECULAR CHARACTERISTICS OF SRSF2-MUTATED NEOPLASMS (2019) (0)
111 MUTATIONAL PROFILE AND KARYOTYPIC ABNORMALITIES OF CLINICAL TRIAL PATIENTS WITH HIGHER-RISK MDS FOLLOWING FAILURE OF HYPOMETHYLATING AGENTS (HMAS): IMPACT ON RESPONSE TO RIGOSERTIB THERAPY (2015) (0)
SF3B1 MUTATIONS IN MDS-RS ARISE IN MULTIPOTENT HEMOPOETIC STEM CELLS (2016) (0)
Gene Expression Profiling of CD34(+) Cells in Patients with Myelodysplastic Syndromes (2008) (0)
259 The clonal advantage of del(5q) MDS stem cells is mediated by increased adhesion to the microenvironment (2011) (0)
Functional and Molecular Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Patients with Myelodysplastic Syndrome with Ring Sideroblast (2016) (0)
S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B (2022) (0)
Health-Related Quality of Life is Substantially Impaired in Lower-Risk MDS when Compared with Reference Populations and Significantly Affects Overall Survival (2017) (0)
Abstract 3092: Activation of evolutionarily young transposable elements and the host innate immune system are linked to clinical response to 5-azacitidine (2019) (0)
74 CHARACTERIZATION OF THE HEMATOPOIETIC STEM AND PROGENITOR CELL HIERARCHY IN MYELODYSPLASTIC SYNDROMES PATIENTS WITH MONOSOMY 7 AS THE SOLE CYTOGENETIC ABNORMALITY (2015) (0)
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution (2021) (0)
The Population-Based ‘real world’ of Low Risk Myelodysplastic Syndromes; Second Interim Analysis of the European LeukemiaNet MDS Registry at 800 Registered New Patients (2010) (0)
Erythropoiesis In SF3B1 Mutated RARS Is Disrupted During Terminal Erythroid Maturation (2013) (0)
Prevalence and Clinical Impact of Additional Cytogenetic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Deletion 5q from the MDS-003 and MDS-004 Studies (2014) (0)
sideroblasts associated with marked thrombocytosis Molecular and clinical features of refractory anemia with ringed (2013) (0)
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment (2021) (0)
Transfusion Patterns during Early Follow-up Predict Overall Survival Independently of IPSS-M in Patients with Myelodysplastic Syndromes (2022) (0)
PF535 CLINICAL AND MOLECULAR CHARACTERISTICS OF SRSF2-MUTATED NEOPLASMS (2019) (0)
212 TRANSFUSIONS AND PRESENCE OF RINGSIDEROBLASTS INFLUENCE HEPCIDIN AND NTBI LEVELS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) - A REPORT FROM THE EUROPEAN LEUKEMIANET MDS REGISTRY (2015) (0)
Sixth International Symposium on Myelodysplastic Syndromes, Stockholm, June 14–17, 2001 (2002) (0)
Identification of a Prognostic Gene Expression Signature for AZA Response in MDS and CMML Patients (2014) (0)
135 Lower bone marrow myeloid and plasmacytoid dendritic cell counts in high-risk than in low-risk MDS patients and controls (2011) (0)
Characterization of the Hematopoietic Stem and Progenitor Cell Hierarchy in Myelodysplastic Syndromes Patients with Monosomy 7 As the Sole Cytogenetic Abnormality (2014) (0)
Randomized Phase II Study and Long-Term Follow-Up of 71 Patients Colony-Stimulating Factor Plus Erythropoietin: Results From a Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte (2009) (0)
Isogenic MDS-RS Patient-Derived iPSCs Define the Mis-Spliced Transcript Repertoire and Chromatin Landscape of SF3B1-Mutant Hematopoietic Stem/Progenitor Cells (2021) (0)
Targeted Sequencing of a Cohort of 385 Patients with Myelodysplastic Syndromes: A Multicenter, Population-Based Study from Sweden (2017) (0)
Biographies of invited faculty (2007) (0)
Multicolor Flowcytometry Analysis of Hematopoietic Stem and Progenitor Cells Subsets Among Basal and Mobilized Peripheral CD34+ Cells (2014) (0)
Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide (2015) (0)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (0)
Germline predisposition to myeloid neoplasms Recommendations for genetic diagnosis, clinical management and follow-up Nordic guidelines (2019) (0)
Characterisation of the Stem and Progenitor Cell Hierarchy in Patients with CMML (2014) (0)
Acquired Somatic Mutations in T Cells in Patients with Aplastic Anemia and Hypoplastic Myelodysplastic Syndromes (2017) (0)
syndromes characterize early erythroid precursors in low-risk myelodysplastic Aberrant mitochondrial iron distribution and maturation arrest (2013) (0)
3108 – MOLECULAR MECHANISMS OF LENALIDOMIDE RESISTANCE IN DEL(5Q) MYELODYSPLASTIC SYNDROMES (2020) (0)
P127 Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC) (2009) (0)
Somatic Mutations in T Cells in Patients with Hematological Diseases (2022) (0)
IVA.2 Managing myelodysplastic syndromes in the frail elderly (2007) (0)
P-005 Aberrant splicing during erythroid differentiation in SF3B1 mutated sideroblastic anemia (2013) (0)
Cytogenetic characteristics predict outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukaemia Groups (2002) (0)
C028 Lenalidomide abrogates the clonal advantage of del(5q) MDS stem cells via alteration of niche interactions (2009) (0)
A Distinct Molecular Signature of Purified Cancer Stem Cells: Evidence for a Hematopoietic Stem Cell Origin of the 5q- Syndrome. (2005) (0)
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia (2018) (0)
Mutations in Histone Modulators and HOXA5 Methylation Levels Affects Survival in Azacitidine Treated MDS Patients (2014) (0)
Combined DNA and Transcriptome Sequencing Reveals Discrete Subtypes of Myelodysplasia (2016) (0)
The Clinical Picture of the ERCC6L2 Disease - from Bone Marrow Failure to Acute Leukemia. (2023) (0)
Efficient Scale-up and Pre-Clinical Evaluation of NKG2C+ Adaptive NK Cell Expansion for Therapy Against High-Risk AML/MDS (2018) (0)
Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment (2011) (0)
The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS (2022) (0)
380 Characterisation and targeting of malignant stem cells in myelodysplastic syndromes (2011) (0)
Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004 (2013) (0)
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression) (2021) (0)
P015 European LeukemiaNet registry programme for low/INT-1 IPSS score myelodysplastic syndromes (2009) (0)
Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia (2022) (0)
Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death (2018) (0)
Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10) (2022) (0)
Early and Transient Microchimerism Associated with Complete Remission after Adoptively Transferred Haploidentical NK Cells Against High Risk Myelodysplastic Syndrome and Refractory Acute Myeloid Leukemia (2014) (0)
P-106 Pharmacodynamic study of 5-azacytidine (2005) (0)
165 RECURRENT MUTATIONS AS WELL AS CLONAL EVOLUTION ARE COMMON IN PATIENTS WITH LOWER-RISK MDS AND DEL(5Q) TREATED WITH LENALIDOMIDE (2015) (0)
Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective. (2023) (0)
69 Hypomethylation of a non-coding RNA on chromosome 5q31.1 is a positive prognostic factor for survival in AML/high risk MDS (2011) (0)
Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases (2022) (0)
51 PROGNOSTIC IMPACT OF TRANSFUSION INTENSITY ON SURVIVAL AND THROMBOCYTOPENIA IN NEWLY DIAGNOSED LOWER-RISK MDS PATIENTS PARTICIPATING IN THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY (2015) (0)
P-098 p53 protein expression predicts outcome and cytogenetic response in patients with low-/INT-1-risk myelodysplastic syndromes treated with lenalidomide (2013) (0)
Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies (2015) (0)
152 Clinical results of the use of different cytokines in MDS (1997) (0)
54 ADOPTIVELY TRANSFERRED HAPLOIDENTICAL NK CELLS AGAINST REFRACTORY MDS, HIGH-RISK MDS AND REFRACTORY AML AS A BRIDGE TO TRANSPLANTATION. COMPLETE REMISSION ASSOCIATED WITH DETECTABLE NK CELLS (2015) (0)
171 Complex effects of azacitidine in primary myelodysplastic and normal bone marrow cell cultures (2011) (0)
YI1 Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets (2009) (0)
Erythroid differentiation intensifies RNA mis-splicing in SF3B1-mutant myelodysplastic syndromes with ring sideroblasts (2023) (0)
An Integrative Genomics Approach Uncovers the Basis of Resistance to AZA Therapy in MDS and CMML (2015) (0)
Hierarchical Analysis Of Recurrent Point Mutations In SF3B1 and TET2 In RARS Stem Cells (2013) (0)
Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry (2015) (0)
The extent of residual WT hematopoietic stem and progenitor cells is associated with the degree of anemia in SF3B1-mutated MDS-RS patients. (2022) (0)
5q- myelodysplastic syndromes The molecular signature of MDS stem cells supports a stem cell origin of (2010) (0)
Expression Profiling of CD34+ Cells in Patients with Myelodysplastic Syndromes: Involvement of Interferon-Stimulated Genes and Correlation to FAB Subtype and Karyotype. (2006) (0)
Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome (2020) (0)
Recombinant human erythropoietin (rhEPO) therapy in myelodysplasia (2008) (0)
Hepcidin and GDF15 Levels during the First 2 Years Follow-up in Patients with Low and Int-1 Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry (2014) (0)
Title Aberrant splicing and defective mRNA production induced bysomatic spliceosome mutations in myelodysplasia (2019) (0)
Erythropoiesis Is Highly Stimulated in CD34 + Cells in Low-Risk Myelodysplastic Syndromes (MDS) with an Improper Mitochondrial Function. (2004) (0)
Diverse Genetic Lesions In Myelodysplastic Syndromes Originate Exclusively In Rare MDS Stem Cells (2013) (0)
Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes (2023) (0)
Comparative trial of aazacitidine versus conventional care in high risk MDS patients: Methodologic challenges in designing an international survival trial. (2003) (0)
COMPREHENSIVE ANALYSIS OF MUTATION STATUS, GENE EXPRESSION PROFILES, BLOOD AND BONE MARROW COUNTS AND OUTCOME IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (2014) (0)
Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q) (2008) (0)
Genetic Determinants of Disease Phenotype and Clinical Outcome in Myelodysplastic Syndromes with Ring Sideroblasts (2014) (0)
49 ABCB7 plays an essential role in sideroblast formation in acquired refractory anemia with ring sideroblasts (2011) (0)
Progression in Patients with with Low- and Intermediate-1 Risk Del(5q) MDS Is Predicted By a Limited Subset of Mutations (2016) (0)
Transcriptome Analysis of Differentiating Erythroid Progenitors in Refractory Anemia with Ringed Sideroblasts (2010) (0)
RUNX1 Loss of Function Drives Resistance to Lenalidomide in Del(5Q) Myelodysplastic Syndrome Patients (2017) (0)
P-110 Evaluation of a high throughput mutation-screening strategy in myelodysplastic syndrome patients and acute myeloid leukemia using Halogenomics™ targeted-gene enrichment technology (2013) (0)
From Mild Cytopenia to Overt MDS and AML, the Mutational Profile Predicts Progression, but Not Survival (2018) (0)
adults : recommendations from the European LeukemiaNet Diagnosis and treatment of primary myelodysplastic syndromes in (2013) (0)
A New Prognostic Disease Specific Model To Predict Survival after Intensive Antileukemic Treatment for Young Patients with Poor-Risk MDS and AML: Results of the CRIANT and AML-10 Studies Conducted by the EORTC/GIMEMA/SAKK/HOVON/EBMT Groups. (2004) (0)
Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine. (2012) (0)
Value of allogeneic stem cell transplantation (SCT) versus autologous SCT and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial (2010) (0)
Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS (2022) (0)
217 DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE (2015) (0)
VALIDATION OF PROGNOSTIC SCORING SYSTEMS FOR MYELODYSPLASTIC SYNDROMES IN THE SWEDISH MDS-REGISTER (2016) (0)
Benchmarking variant calling tools for NGS data (2017) (0)
O-027 European distribution of usage and impact on outcome for treatment with erythropoietic stimulating agents within the EUMDS lower-risk registry programme (2013) (0)
O-49 Management of the anemia of MDS (2005) (0)

This paper list is powered by the following services:

Eva Hellström‐lindberg's Academic­Influence.com Rankings

Why Is Eva Hellström‐lindberg Influential?

Eva Hellström‐lindberg's Published Works

Published Works

Eva Hellström‐lindberg's AcademicInfluence.com Rankings